Global HER2+ Gastric Cancer Market is Segmented By Therapy (Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy), By Stage (Stage I, Stage II, Stage III, Stage IV), By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
HER2+ Gastric Cancer Market Overview
Global HER2+ Gastric Cancer Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
HER2 overexpression is increasingly recognized as a frequent molecular abnormality, driven as in breast cancer by gene amplification. There is mounting evidence of the role of HER2 overexpression in patients with gastric cancer, and it has been solidly correlated to poor outcomes and a more aggressive disease. HER2-positive gastric cancer is a subtype of gastric cancer that overexpresses the HER2 protein. HER2-targeted therapy has been shown to improve the prognosis for patients with HER2-positive gastric cancer.
HER2+ Gastric Cancer Market Scope
|
Metrics |
Details |
|
CAGR |
YY% |
|
Size Available for Years |
2021-2030 |
|
Forecast Period |
2023-2030 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Therapy, Stage, End User |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details of the report- Request for sample
Market Dynamics: Drivers and Restraints
Advancements in treatment options
Biomarkers for effective treatment of advanced gastric cancer (GC) include HER2 overexpression, MSI/PD-L1 status, and FGFR alterations. Despite the success of the ToGA trial, anti-HER2 agents have not significantly improved clinical outcomes. The FDA has accelerated the approval of pembrolizumab in combination with trastuzumab plus chemotherapy for HER2-positive advanced gastric or GEJ cancer patients.
Combining anti-HER2 mAb with immunotherapy is a reasonable strategy to overcome immune insensitivity in AGC patients. T-DXd is effective in patients who have received two previous lines of treatment. Assessing HER2 status in GC patients is challenging due to their multiple heterogeneities. HER2 amplification level may be a predictive biomarker for selecting patients who can benefit most from HER2 targeted therapies. Tumor NGS, ctDNA, and other biomarkers may clarify the population that can derive the most clinical benefit from anti-HER2 agents.
Furthermore, the HER2+ gastric cancer market is also driven by various other factors like rise in biomarker therpaies, increase in clinical trails and others help the market to grow during the forecast period.
Restraint
Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges which hamper the market growth during the forecast period. The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.
HER2+ Gastric Cancer Market Segmentation
The global HER2+ gastric cancer market is segmented based on therapy, stage, end-user and region.
The immunotherapy from the therapy segment accounted for approximately 39.7% of the HER2+ gastric cancer market share
The immunotherapy from the therapy segment accounted for approximately 39.7% and is expected to dominate during the forecast period. The treatment landscape of HER2-positive gastric cancer has evolved over recent years, especially with the introduction of novel anti-HER2 drugs and combination strategies. The use of immunotherapy in combination with anti-HER2 agents demonstrates a strong preclinical rationale, and clinical trials have produced encouraging results. Additionally, the diverse therapeutic drugs under development mark an exciting era in the management of HER2-positive disease.
Global HER2+ Gastric Cancer Market Geographical Share
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like the rising prevalence of gastric cancer, FDA approvals, advanced healthcare technology and others that help the region to be highest market share during the forecast period.
For instance, Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease. Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.
Moreover, in May 2020, AstraZeneca and Daiichi Sankyo Company, Limited was granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
COVID-19 Impact Analysis
The COVID-19 pandemic has put cancer patients at risk of adverse outcomes due to delays in diagnosis and treatment. Experienced multidisciplinary teams have had a critical role in tailoring management to ensure oncological outcomes and quality of life for these patients. While in high-income countries gastric cancer surgical treatment could be safely delayed provided that neoadjuvant treatment (NAT) was administered, in low-medium-income countries where patients could not receive either NAT or surgery, these delays could lead to increased recurrence rates and excess mortality.
Competitive Landscape
The major global players in the market include Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG and among others.
Key Developments
- In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd jointly stated, that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted a Breakthrough Therapy designation to KN026 (HER2 bispecific antibody) combined with chemotherapy for the treatment of HER2-positive gastric cancer (including gastroesophageal junction cancer).
- In December 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Why Purchase the Report?
- To visualize the global HER2+ gastric cancer market segmentation based on therapy, stage, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of HER2+ gastric cancer market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global HER2+ gastric cancer market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
